ClinicalTrials.gg
CompletedNCT01466387Updated Mar 11, 2014Results posted

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

A Phase 3 interventional study of Typhoid Vi Polysaccharide Vaccine and Yellow Fever Vaccine in Meningococcal Disease, Meningococcal Meningitis and Typhoid, sponsored by Novartis. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-11.

Primary conditionMeningitis, MeningococcalRegistry: Meningococcal InfectionsReclassifiedWhy we changed it
Registry
Meningococcal Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningococcal Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
552
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.

Enrollment
18th of 30
552 · median 707
Started
2011
with 8 others
Phase 3
19 of 32
none open now
Registered
28th of 32
by date

Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 18th largest by enrollment of the 30 interventional ones that give a count, is one of 9 that started in 2011, is one of 19 in phase 3, and was the 28th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Meningitis, Meningococcal by Novartis as a file.
02

Study summary

This study compares the safety and immunogenicity profile of several travel vaccines given alone or concomitantly with MenACWY-CRM to healthy adults.

03

Conditions studied

  • Meningococcal Disease
  • Meningococcal Meningitis
  • Typhoid
  • Yellow Fever
  • Rabies
  • Japanese Encephalitis

Keywords

  • Adults
  • international travel vaccination
  • Meningococcal disease
  • meningococcal meningitis
  • typhoid
  • yellow fever
  • rabies
  • Japanese encephalitis
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 552 is close to the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningococcal Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female and male subjects who must be healthy and must be:

  1. Between 18 and 60 years of age inclusive and who have given their written ;
  2. Available for all visits and telephone calls scheduled for the study;
  3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;
  4. For female subjects, having a negative urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

Individuals not eligible to be enrolled in the study are those:

  1. who are breastfeeding;
  2. who have a personal history of Neisseria meningitidis infection, typhoid fever, rabies, or any flavivirus infection (e.g., Japanese encephalitis, tick-borne encephalitis, yellow fever, dengue fever, West Nile virus infection);
  3. who have been immunized with any of the study vaccines within the last five years as determined by medical history and/or vaccination card;
  4. who have received agents or vaccines within 30 days prior to enrollment or who expect to receive an investigational agent or vaccine prior to completion of the study;
  5. who have received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine is anticipated during the study period.

    (Exception: Influenza vaccine may be administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization);

  6. who have received an anti-malaria drug, up to 2 months prior to the study;
  7. who have experienced, within the 7 days prior to enrollment, significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or have experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment;
  8. who have any serious acute, chronic or progressive disease such as:

    • history of cancer
    • complicated diabetes mellitus
    • advanced arteriosclerotic disease
    • disease
    • infection or AIDS
    • blood dyscrasias
    • congestive heart failure
    • renal failure
    • severe malnutrition (Note: Subjects with mild asthma are eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic are not eligible for enrollment);
  9. who have epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome;
  10. who have a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including but not limited to latex allergy, egg allergy, antibiotic allergy, chicken proteins or gelatin allergy;
  11. who have a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):

    • receipt of therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);
    • receipt of immunostimulants;
    • receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study;
  12. who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time;
  13. who have myasthenia gravis; thyroid or thymic disorders,
  14. who have any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives;
  15. who are part of the study personnel or close family members of those conducting this study.
  16. for whom a long-term stay (≥ 1 month) was planned in Africa, Latin America, or Asia.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
552 participants (actual)

Study arms

  • Active comparator
    TF+YF

    Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.

    Biological: Typhoid Vi Polysaccharide Vaccine · Biological: Yellow Fever Vaccine

  • Active comparator
    TF + YF + MenACWY-CRM197

    Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.

    Biological: Typhoid Vi Polysaccharide Vaccine · Biological: Yellow Fever Vaccine · Biological: MenACWY-CRM Vaccine

  • Active comparator
    JE + Rabies

    Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.

    Biological: Japanese Encephalitis Vaccine · Biological: Rabies Vaccine

  • Active comparator
    JE + Rab + MenACWY-CRM197

    Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.

    Biological: Japanese Encephalitis Vaccine · Biological: Rabies Vaccine · Biological: MenACWY-CRM Vaccine

  • Active comparator
    Rabies

    Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.

    Biological: Rabies Vaccine

  • Active comparator
    MenACWY-CRM197 (Combined)

    Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.

    Biological: MenACWY-CRM Vaccine

Interventions

  • One dose of typhoid Vi polysaccharide vaccine.

  • One dose of yellow fever vaccine.

  • BiologicalJapanese Encephalitis Vaccine

    Two doses of Japanese Encephalitis Vaccine.

  • BiologicalRabies Vaccine

    Three doses of Rabies vaccine.

  • BiologicalMenACWY-CRM Vaccine

    One dose of MenACWY-CRM vaccine.

07

What researchers measure

Primary outcomes

  1. Geometric Mean Anti-typhoid Vi Antibody Concentrations

    Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.

    Time frame: Baseline and 1 month postvaccination (day 29).

  2. Geometric Mean Anti-Yellow Fever Antibody Titer

    Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.

    Time frame: Baseline and 1 month postvaccination (day 29).

  3. Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers

    Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.

    Time frame: Baseline and 1 month post last vaccination (day 57).

  4. Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration

    Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.

    Time frame: Baseline and 1 month post last vaccination (day 57).

Secondary outcomes

  1. Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone

    Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29. Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.

    Time frame: Baseline and 1 month postvaccination (day 29).

  2. Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone

    Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.

    Time frame: Baseline and 1 month post last vaccination (day 57).

  3. Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone

    Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.

    Time frame: Baseline and 1 month post last vaccination (day 57).

  4. Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone

    Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.

    Time frame: Baseline and 1 month postvaccination (day 29).

  5. Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone

    Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone. Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.

    Time frame: 1 month postvaccination (day 29)

  6. Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone

    Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.

    Time frame: Baseline and 1 month post last vaccination (day 29 or day 57).

  7. Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone

    Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone. Seroresponse is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.

    Time frame: 1 month post last vaccination (day 29 or day 57)

  8. Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197

    The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.

    Time frame: Baseline and 1 month post last vaccination (day 57).

  9. Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197

    Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines. Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.

    Time frame: Baseline and 1 month post last vaccination (day 57).

  10. Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone

    In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.

    Time frame: day 1 to day 57 post last vaccination

08

Results

Posted Mar 11, 2014

Participant flow

Subjects were enrolled at 5 sites (Berhard Nocht Institut, Germany, Berliner Centrum fuer Reise, Germany, Universitat Rostock, Germany, University of Munich, Germany, Vacc and Travel Med. Center, Czech Republic)

Participant flow — Overall Study
MilestoneTF+YFTF+YF+MenACWY-CRM197JE+RabiesJE+Rabies+MenACWY-CRM197RabiesMenACWY-CRM197 (Combined)
Started1011009910151100
Completed10010098995199
Not completed101201
Withdrew: Adverse event001100
Withdrew: Lost to follow-up000001
Withdrew: Protocol violation100100

Outcome measures

PrimaryGeometric Mean Anti-typhoid Vi Antibody Concentrations

Assessment was made to demonstrate the non-inferiority of the geometric mean anti-typhoid Vi antibody concentrations, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.

Time frame:
Baseline and 1 month postvaccination (day 29).
Reported as:
Geometric mean · El.U/mL
Geometric Mean Anti-typhoid Vi Antibody Concentrations
El.U/mLTF+YFTF+YF+MenACWY-CRM197
Day 1 (Typhoid Fever)6.37 (5.3 to 7.65)5.6 (4.66 to 6.73)
Day 29 (Typhoid Fever)134 (104 to 174)153 (118 to 197)
Statistical analysis
  • TF+YF vs TF+YF+MenACWY-CRM197 · ANCOVA · Ratio of gmc: 1.14 · 95% CI 0.81 to 1.6The ANCOVA model included vaccine group and center as factors, age as covariate and was adjusted for baseline.
PrimaryGeometric Mean Anti-Yellow Fever Antibody Titer

Assessment was made to demonstrate the non-inferiority of the geometric mean anti-yellow fever antibody titers, 28 days after the vaccination of typhoid Vi polysaccharide (TF) and yellow fever (YF) vaccines given concomitantly with MenACWY-CRM197 to typhoid Vi polysaccharide and yellow fever vaccines given alone in healthy adults aged ≥18 years to ≤60 years.

Time frame:
Baseline and 1 month postvaccination (day 29).
Reported as:
Geometric mean · Titers
Geometric Mean Anti-Yellow Fever Antibody Titer
TitersTF+YFTF+YF+MenACWY-CRM197
Day 1 (Yellow Fever)9.05 (6.82 to 12)12 (8.68 to 15)
Day 29 (Yellow Fever)5244 (3929 to 7000)5022 (3754 to 6717)
Statistical analysis
  • TF+YF vs TF+YF+MenACWY-CRM197 · ANCOVA · Ratio of gmt.: 0.96 · 95% CI 0.65 to 1.41The ANCOVA model included vaccine group and center as factors, age as covariate and was adjusted for baseline.
PrimaryGeometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers

Assessment was made to demonstrate the non-inferiority of the geometric mean anti-Japanese encephalitis neutralizing antibody titers, 28 days after the vaccination of the second dose of Japanese Encephalitis vaccine and third dose of the rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Geometric mean · Titers
Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers
TitersJE+RabiesJE+Rab+MenACWY-CRM197
Day 1 (Japanese Encephalitis)5.61 (5.11 to 6.15)5.58 (5.09 to 6.12)
Day 57 (Japanese Encephalitis)183 (151 to 221)165 (136 to 199)
Statistical analysis
  • JE+Rabies vs JE+Rab+MenACWY-CRM197 · ANCOVA · Ratio of gmt: 0.9 · 95% CI 0.7 to 1.16The ANCOVA model included vaccine group and centers as factors, age as covariate and was adjusted for baseline.
PrimaryGeometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration

Assessment was made to demonstrate the non-inferiority of the geometric mean anti-rabies virus neutralizing antibody concentrations, 28 days after the vaccination of the second dose of Japanese encephalitis vaccine and third dose of rabies virus vaccine given concomitantly with MenACWY-CRM197 or alone in healthy adults aged ≥18 years to ≤60 years.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Geometric mean · IU/mL
Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration
IU/mLJE+RabiesJE+Rab+MenACWY-CRM197
Day 1 (Rabies)0.056 (0.05 to 0.062)0.049 (0.044 to 0.054)
Day 57 (Rabies)12 (9.68 to 14)11 (8.84 to 13)
Statistical analysis
  • JE+Rabies vs JE+Rab+MenACWY-CRM197 · ANCOVA · Ratio of gmc: 0.91 · 95% CI 0.71 to 1.17The ANCOVA model included vaccine group and center as factors, age as covariate and was adjusted for baseline.
SecondaryPercentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone

Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-YF neutralizing antibody titers after the vaccination of typhoid Vi polysaccharide and yellow fever, given alone or concomitantly with MenACWY-CRM197 on day 29. Seroprotection is defined as percentages of subjects who achieved anti-YF neutralizing antibody titers ≥ 1/10 on day 29.

Time frame:
Baseline and 1 month postvaccination (day 29).
Reported as:
Number · Percentages of subjects
Percentages Of Subjects With Anti-YF Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of Typhoid Vi Polysaccharide And Yellow Fever, Concomitantly With MenACWY-CRM197 Or Given Alone
Percentages of subjectsTF+YFTF+YF+MenACWY-CRM197
Day 1 (Yellow Fever)34 (25 to 44)36 (27 to 46)
Day 29 (Yellow Fever)100 (96 to 100)97 (91 to 99)
SecondaryPercentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone

Immunogenicity was measured as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-Japanese encephalitis neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as percentages of subjects who achieved anti-JE neutralizing titers ≥ 1/10 on Day 57.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Number · Percentages of subects
Percentages Of Subjects With Anti-JE Neutralizing Antibody Titers ≥ 1/10, 28 Days After The Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies, Given Concomitantly With MenACWY-CRM197 Or Alone
Percentages of subectsJE+RabiesJE+Rabies+MenACWY-CRM197
Day 1 (Japanese Encephalitis)3 (1 to 9)4 (1 to 10)
Day 57 (Japanese Encephalitis)99 (94 to 100)98 (93 to 100)
SecondaryPercentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone

Immunogenicity was assessed as the percentages of subjects who achieved seroprotection as measured by neutralization test for anti-rabies neutralizing antibody titers, 28 days after administration of the second dose of Japanese encephalitis virus vaccine and 28 days after the vaccination of third dose of rabies virus vaccine, given alone or concomitantly with MenACWY-CRM197. Seroprotection is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a post-vaccination hSBA titer of at least 4 times the baseline.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Number · Percentages of subjects
Percentages Of Subjects With Anti-Rabies Virus Antibody Concentrations ≥ 0.5 IU/mL 28 Days After the Vaccination Of The Last Doses Of Japanese Encephalitis And Rabies Virus, Given Concomitantly With MenACWY-CRM197 Or Alone
Percentages of subjectsJE+RabiesJE+Rabies+MenACWY-CRM197
Day 1 (Rabies)3 (1 to 9)1 (0.026 to 5)
Day 57 (Rabies)100 (96 to 100)100 (96 to 100)
SecondaryGeometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone

Immunogenicity was assessed by Serum Bactericidal Assay using human complement (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone.

Time frame:
Baseline and 1 month postvaccination (day 29).
Reported as:
Geometric mean · titers
Geometric Mean hSBA Titers For Meningococcal Serogroups A,C,W,Y 28 Days After The Vaccination Of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide And Yellow Fever Vaccines Alone
titersMenACWY-CRM197 (Combined)TF+YF+MenACWY-CRM197
Serogroup A (Day 1)2.94 (2.43 to 3.56)2.78 (2.3 to 3.36)
Serogroup A (Day 29)65 (44 to 95)62 (42 to 90)
Serogroup C (Day 1)7.94 (5.94 to 11)7.03 (5.27 to 9.38)
Serogroup C (Day 29)49 (35 to 70)54 (38 to 76)
Serogroup W (Day 1)50 (35 to 71)32 (22 to 45)
Serogroup W (Day 29)129 (94 to 177)211 (154 to 290)
Serogroup Y (Day 1)7.61 (5.71 to 10)7.76 (5.83 to 10)
Serogroup Y (Day 29)89 (62 to 129)78 (54 to 113)
SecondarySeroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone

Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with typhoid Vi polysaccharide and yellow fever vaccines or alone. Seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥1:4, seroresponse is defined as a postvaccination hSBA titer of at least four times the baseline.

Time frame:
1 month postvaccination (day 29)
Reported as:
Number · Percentages of subjects
Seroresponse Rate For Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Typhoid Vi Polysaccharide and Yellow Fever Vaccines or Alone
Percentages of subjectsTF + YF + MenACWY-CRM197MenACWY-CRM197 (Combined)
Serogroup A (Overall Seroresponse)72 (62 to 81)71 (61 to 79)
Serogroup C (Overall Seroresponse)48 (38 to 58)47 (37 to 58)
Serogroup W (Overall Seroresponse)51 (40 to 61)30 (21 to 40)
Serogroup Y (Overall Seroresponse)63 (53 to 72)66 (55 to 75)
SecondaryGeometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone

Immunogenicity was measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone.

Time frame:
Baseline and 1 month post last vaccination (day 29 or day 57).
Reported as:
Geometric mean · titers
Geometric Mean hSBA Titers for Meningococcal Serogroups A,C,W,Y 28 Days After the Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone
titersJE + Rab + MenACWY-CRM197MenACWY-CRM197 (Combined)
Serogroup A (Day 1)3.21 (2.65 to 3.88)2.94 (2.43 to 3.56)
Serogroup A (Day 29 or Day 57)32 (22 to 47)65 (44 to 95)
Serogroup C (Day 1)8.81 (6.59 to 12)7.94 (5.94 to 11)
Serogroup C (Day 29 or Day 57)44 (31 to 62)49 (35 to 70)
Serogroup W (Day 1)54 (38 to 77)50 (35 to 71)
Serogroup W (Day 29 or Day 57)119 (87 to 164)129 (94 to 177)
Serogroup Y (Day 1)8.11 (6.08 to 11)7.61 (5.71 to 10)
Serogroup Y (Day 29 or Day 57)55 (38 to 80)89 (62 to 129)
SecondarySeroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone

Immunogenicity was assessed by seroresponse rates as measured by human serum bactericidal activity (hSBA) titers for meningococcal serogroups A,C,W,Y 28 days after administration of MenACWY-CRM197 given concomitantly with Japanese encephalitis and rabies virus vaccines or alone. Seroresponse is defined as a subject with a baseline hSBA titer \< 1:4, seroresponse was defined as a post-vaccination hSBA titer ≥ 1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse was defined as a postvaccination hSBA titer of at least 4 times the baseline.

Time frame:
1 month post last vaccination (day 29 or day 57)
Reported as:
Number · Percentages of subjects
Seroresponse Rate for Meningococcal Serogroups A,C,W,Y 28 Days After Vaccination of MenACWY-CRM197 Given Concomitantly With Japanese Encephalitis and Rabies Virus Vaccines or Alone
Percentages of subjectsJE + Rab + MenACWY-CRM197MenACWY-CRM197 (Combined)
Serogroup A (Overall Seroresponse)60 (49 to 69)71 (61 to 79)
Serogroup C (Overall Seroresponse)43 (33 to 54)47 (37 to 58)
Serogroup W (Overall Seroresponse)32 (23 to 42)30 (21 to 40)
Serogroup Y (Overall Seroresponse)56 (45 to 66)66 (55 to 75)
SecondaryGeometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197

The immunogenicity was assessed in rabies virus vaccine as measured by geometric mean rabies virus neutralizing antibody concentration, 28 days after vaccination of the third dose, when administered alone or concomitantly either with Japanese encephalitis vaccine or with Japanese Encephalitis and MenACWY-CRM197 vaccines.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Geometric mean · IU/mL
Geometric Mean Rabies Virus Neutralizing Antibody Concentration 28 Days After the Last Vaccination Of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis And MenACWY-CRM197
IU/mLJE + Rabies + MenACWY-CRM197JE + RabiesRabies
Day 1 (Rabies)0.051 (0.044 to 0.059)0.057 (0.049 to 0.065)0.068 (0.056 to 0.082)
Day 57 (Rabies)11 (8.84 to 13)11 (9.49 to 14)8.97 (6.98 to 12)
SecondaryPercentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197

Immunogenicity was measured as the percentages of subjects who achieved seroprotection of anti-rabies virus antibody concentrations 28 days after vaccination of the third dose of rabies virus vaccine, when administered alone or concomitantly either with Japanese encephalitis or with Japanese encephalitis and MenACWY-CRM197 vaccines. Seroprotection is defined as percentages of subjects who achieved anti-rabies virus antibody concentrations ≥ 0.5 IU/mL on day 57.

Time frame:
Baseline and 1 month post last vaccination (day 57).
Reported as:
Number · Percentages of subjects
Percentages of Subjects With Anti-rabies Virus Concentrations ≥ 0.5 IU/mL, 28 Days After the Last Vaccination of Rabies Virus Vaccine Concomitantly Either With Japanese Encephalitis or With Japanese Encephalitis and MenACWY-CRM197
Percentages of subjectsJE + Rabies + MenACWY-CRM197JE + RabiesRabies
Day 1 (Rabies)1 (0.026 to 5)3 (1 to 9)8 (2 to 19)
Day 57 (Rabies)100 (96 to 100)100 (96 to 100)100 (93 to 100)
SecondaryNumber of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone

In addition to the AEs and SAEs. Additional AESI were collected from day 1 to day 57 postvaccination in subjects after the vaccination of Japanese encephalitis and rabies virus vaccines given concomitantly with MenACWY-CRM197 or alone.

Time frame:
day 1 to day 57 post last vaccination
Reported as:
Number · subjects
Number of Subjects With Adverse Events of Special Interest After Any Vaccination of Japanese Encephalitis and Rabies Virus Vaccines Given Concomitantly With MenACWY-CRM197 or Alone
subjectsJE + Rabies + MenACWY-CRM197JE + Rabies
Injection site erythema01
Hypersensitivity10
Paresthesia01
Erythema10
Pruritus11
Hot flush10

Adverse events

Collected over day 1 to day 29 (one month postvaccination); day 1 to day 57 (one month post last vaccination). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TF+YF—0/101 (0%)27/101 (26.7%)
TF+YF+MenACWY-CRM197—0/100 (0%)30/100 (30%)
JE+Rabies—1/99 (1%)23/99 (23.2%)
JE+Rabies+MenACWY-CRM197—1/101 (1%)22/101 (21.8%)
Rabies—0/51 (0%)9/51 (17.6%)
MenACWY-CRM197 (Combined)—0/100 (0%)9/100 (9%)
Most frequent serious events
Most frequent serious events
EventTF+YFTF+YF+MenACWY-CRM197JE+RabiesJE+Rabies+MenACWY-CRM197RabiesMenACWY-CRM197 (Combined)
InjuryInjury, poisoning and procedural complications0/1010/1001/990/1010/510/100
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1010/1000/991/1010/510/100
Most frequent other events
Most frequent other events
EventTF+YFTF+YF+MenACWY-CRM197JE+RabiesJE+Rabies+MenACWY-CRM197RabiesMenACWY-CRM197 (Combined)
Injection site painGeneral disorders12/1018/1006/994/1012/512/100
HeadacheGeneral disorders7/10110/1009/995/1015/514/100
Influenza like illnessGeneral disorders5/1019/1005/996/1010/512/100
NasopharyngitisInfections and infestations3/1013/1003/997/1012/511/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)TF+YFTF+YF+MenACWY-CRM197JE+RabiesJE+Rabies+MenACWY-CRM197RabiesMenACWY-CRM197 (Combined)Total
Mean36.5 ± 10.835.1 ± 11.035.0 ± 11.535.0 ± 11.135.8 ± 11.636.9 ± 11.235.7 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)TF+YFTF+YF+MenACWY-CRM197JE+RabiesJE+Rabies+MenACWY-CRM197RabiesMenACWY-CRM197 (Combined)Total
Female494453502150267
Male525646513050285
09

Study locations

5 sites
  • Centrum ockovani a cestovni mediciny (Vaccination and Travel Medicine Centre) Poliklinika II
    Bratri Stefanu 895, Hradec Kralove 500 03, Czech Republic
  • Berliner Centrum Fur Reise und Tropenmedizin
    Jaegerstrasse 67-69, Berlin 10117, Germany
  • Bernhard Nocht Strasse 74, Hamburg 20359, Germany
  • University of Munich Georgenstr.5
    Muenchen, 80799, Germany
  • Universitat Rostock, Ernst Heydemann Str 6
    Rostock, 18057, Germany
10

References and documents

Publications

  • Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Hlavata LC, Forleo-Neto E, Dagnew AF, Arora AK. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults. J Travel Med. 2015 Jan-Feb;22(1):48-56. doi: 10.1111/jtm.12164. Epub 2014 Oct 13. PubMed 25308927 ↗
  • Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, Forleo-Neto E, Gniel D, Dagnew AF, Arora AK. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study. Travel Med Infect Dis. 2014 Sep-Oct;12(5):485-93. doi: 10.1016/j.tmaid.2014.04.011. Epub 2014 May 9. PubMed 24873986 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 11 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2011
First posted
Nov 8, 2011
Start
Nov 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results delay requested
Nov 28, 2012
Results first posted
Mar 11, 2014
Last update
Mar 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01466387
Lead sponsor
Novartis
Collaborators
Novartis Vaccines
Responsible party
Sponsor
First posted
Nov 8, 2011
Start date
Nov 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Mar 11, 2014
Last update
Mar 11, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vi polysaccharide vaccine, typhoid · Yellow Fever Vaccine

Start the discussion